search
Back to results

SCI-Pex Study - Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids (SCI-Pex)

Primary Purpose

Hemorrhoids, Hemorrhoids, Internal, Suture; Complications, Infection or Inflammation

Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
PexyEazy
Sponsored by
Developeration AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemorrhoids focused on measuring PexyEazy

Eligibility Criteria

18 Years - 84 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult Hemorrhoidal disease grade II and III American Society of Anesthesiologists (ASA) classification I-III. Exclusion Criteria: Previous surgical treatment for hemorrhoids by all methods except rubber band ligation or sclerosing injection therapy within the last 3 years. Previous surgical treatment with rubber band ligation or injection therapy within the last 2 months. More than three surgical treatments with rubber band ligation or sclerosing injection therapy within the last 3 years. Under medication with immunosuppressive drugs and/or anticoagulant drugs (not including 75mg acetylsalicylic acid) and not able to interrupt the anticoagulant drug medication or replace it with low molecular weight heparin for 5 days. Have ulcerative colitis, Crohn's disease or other intestinal inflammatory disease or presence of inflamed or thickened mucosa of the rectum. Presence of anal fissure, anal stenosis, stricture, fistulas or ulcers in the rectal area. The rectum has not been prepared prior to the investigation with rectal enema and is contaminated with feces that cannot easily be removed. Have schizophrenia, untreated depression or other mental illness or conditions that may affect judgment, sensation of pain or inability to complete the follow-up. Under medication of morphine or other strong painkillers, not including paracetamol. Fecal incontinence (not including soiling due to hemorrhoidal disease), or conditions with impaired sensation in the rectal area or impaired function of the anal sphincter. Previous rectal radiation. Rectal cancer or previous surgery due to rectal cancer. Pregnancy Hypercoagulability disorders or diseases that result in increased risk of bleeding. Impaired immune system or condition that increases the risk of infection.

Sites / Locations

  • Frölunda SpecialistsjukhusRecruiting
  • Norrtälje Sjukhus

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PexyEazy procedure

Arm Description

PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.

Outcomes

Primary Outcome Measures

Surgical result
Clinical evaluation that a proper mucopexy has been achieved above all three locations (3, 7 and 11 o'clock) and any signs of bleeding or other damage to the mucosa, which is documented by the surgeon and by photography.
Validation of device
The handling and performance of the device is validated through a questionnaire that the surgeon fills out after the procedure.
Registered duration of surgery
Duration of surgery (minutes)
Presence of pain
The patient fill in a questionnaire with a scale between 1 and 10, where 1 is no pain and 10 is the worst possible pain.
Need of anesthesia, pain relief or local anesthesia
The need for per-operative anesthesia and/or sedation and/or pain relied (morphine) and/or local anesthesia will be registered.
Per-operative complications
Adverse events (both complication and device malfunction) during or directly after the procedure, which will be registered by a questionnaires filled in by patient and surgeon.

Secondary Outcome Measures

Use of pain relief drugs after surgery
The use of pain relief drugs (name of drug, dosage, number/day)
Pain after surgery
The patient fill in a questionnaire with a scale between 1 and 10, where 1 is no pain and 10 is the worst possible pain.
Post operative complications
Registration of any post-operative complications (fecal incontinence, anal stenosis, bleeding, perianal hematoma, urinary retention or incontinence, presence of infection/abscess and assessment by Clavien-Dindo classification).
Clinical outcome
Evaluation of the rectum and anal canal 3 months after the procedure to register presence of complications and recurrence of the hemorrhoidal disease. The result is documented by the surgeon and by a photography of the mucosa.
Change of symptoms
Change of hemorrhoid symptoms through a questionnaire called Hemorrhoidal Disease Symptom Score and Hemorrhoidal Disease Symptom Score (HDSS and HSS). The score can vary between 4-28.The higher the value, the more severe/worse symptoms.
Change in quality of life
Change in quality of life through a questionnaire called 36-Item Short Form Health Survey (SF-36). The score can vary between 0-100.The higher the value, the better quality of life.
Duration of sick-leave/unable to perform normal activities.
The patient fills in a questionnaire about how long and to what degree the patient needed sick-leave or were not able to perform normal activities (in case the patient does not work).

Full Information

First Posted
January 16, 2023
Last Updated
September 14, 2023
Sponsor
Developeration AB
search

1. Study Identification

Unique Protocol Identification Number
NCT05782010
Brief Title
SCI-Pex Study - Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids
Acronym
SCI-Pex
Official Title
SCI-Pex, a Multi-center, Prospective, Non-controlled Investigation to Evaluate the Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 15, 2023 (Actual)
Primary Completion Date
February 28, 2024 (Anticipated)
Study Completion Date
November 30, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Developeration AB

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The SCI-Pex study is a multicenter, prospective, non-controlled investigation on PexyEazy®, a new device for treatment of hemorrhoids based on the mucopexy method. Mucopexy is a well established method where sutures are applied above the hemorrhoids. When knots are tied, the hemorrhoids are lifted inwards to their normal position, which makes them swell down and symptoms disappears. PexyEazy® perform a mukopexy in a semiautomatic, faster and easier way on awake patient in less than 10 minutes. The SCI-Pex study will evaluate the safety and performance of PexyEazy on 35 patients with hemorrhoids grade II and III with a follow-up after 1 week, 3 months and 5 years. Adverse events, pain and other complications will be recorded, quality of life and hemorrhoid symptom questionnaires and clinical examination after 3 months will be monitored to evaluate the result after a PexyEazy® procedure.
Detailed Description
Background: The generally accepted theory of why hemorrhoidal disease (HD) occurs is that the hemorrhoidal cushions slid down in the anal canal (muco-anal prolapse), which allows them to swell up. This creates problems with bleeding, leakage (soiling), itching and pain. Traditionally, severe HD is treated by surgical removal of the hemorrhoids, but the procedure is associated with long recovery time, pain and complications like stenosis and incontinence. Minimal invasive and hemorrhoid preserving surgery has gained popularity during the last two decades with new methods like Procedure for Prolapse and Hemorrhoids (PPH)/Stapled Anopexy and Transanal Hemorrhoidal Dearterialisation (THD)/Hemorrhoidal Artery Ligation and Recto Anal Repair (HAL/RAR). Several studies have shown, thought that mucopexy alone result in equally good result as THD/HAL-RAR. There are several ways to perform a mucopexy with different ways in how the sutures are applied and how many rows of sutures that are done. Other available methods focus on tissue destruction, for example sclerosing injections, laser, radio ablation, or methods with applied electricity that induce heat. These methods make the hemorrhoids to swell down but does not treat the muco-anal prolapse that are present in grade II and III hemorrhoids. PexyEazy® perform a mucopexy in a new, semi-automatic way with the benefit of reducing the cost and time of surgery and is estimated to be able to be conducted without the need of general anesthesia. Method: PexyEazy® is a single-use device for surgical treatment of internal HD grade II and III (according to the Goligher classification). It is based on the mucopexy method, but instead of applying the sutures by hand, the mucosa is folded by the device and then a loop of suture is introduced into the folded mucosa. When knots are applied, the hemorrhoids are lifted inwards, as the folded mucosa above the hemorrhoids is pulled together. Due to that the most proximal suture is longer and deeper and acts as an anchoring stich, the lifting motion is inwards, towards the deeper stitch. When the position of the hemorrhoids is normalized, the venous drainage is improved, and the hemorrhoids swell down, and symptoms disappears. PexyEazy® consists of five major parts: PexyEazy® examination proctoscope, handle with depth setting piston, light shuttle with a led lamp, PexyEazy® Mucopexy Device (MD) and the battery-pack. All parts are sterile, except the re-usable battery-pack. With the examination proctoscope, a correct position of the operation area is set by pushing a depth setting piston, that is part of the handle, towards the skin when the proctoscope is aligned with the dentate line. The handle is then transferred to the MD, which is inserted into the rectum until the depth- setting piston touches the skin, ensuring a correct position of the operation area. The MD have three operation areas that are positioned alongside the device at 3, 7, and 11 o'clock, which corresponds with the position of the three major internal hemorrhoids. Each operation area consists of 5 indentations, 4 smaller and one larger furthest in. The floor of the indentations has small holes, so when vacuum suction is applied within the device, the mucosa is sucked down into the indentations and thereby folding the mucosa above the hemorrhoids. A double needle is then pushed through the folded mucosa and docks with the ends of a loop of a suture that is stored in the suture cassette at the tip the tip of the device. When the needles are retracted, a loop of suture is introduced through the folded mucosa. The position of the sutures starts 10mm above the dentate line thanks to the settings done through the examination proctoscope and the depth setting piston. The sensation of pain is not present 10mm above the dentate line, which enables surgery without anesthesia. The stitches are 4mm wide, 3mm deep and 10mm long in the first four stitches and 6mm deep and 12mm long in the final stitch furthest in. The unit forming the walls of the indentations is divided into three longitudinal parts. When a supportive tray is removed the unit falls apart into three pieces and is removed, leaving the suture in the mucosa. Knots are then applied with a knot pusher, which pulls the folded mucosa together and the hemorrhoids are lifted inwards. The compressed mucosa is estimated to create multiple adhesion points/scar tissues that fixate the hemorrhoid in the new elevated position, ensuring a long-lasting result after the suture is absorbed (60-90 days). A special mucosa spatula is used to push out any protruding mucosa to make extraction of the device easier without damaging the tissue. Number of subjects: 31-35 patients The SCI-Pex study will evaluate the safety and performance of PexyEazy on patients with hemorrhoids grade II and III. For safety reasons will the first 6-10 patients undergo the procedure under general anesthesia and then the procedure will be done on awake patients (25) with 1 week, 3 months and 5 years follow up with questionnaires and a clinical examination after 3 months to document result.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhoids, Hemorrhoids, Internal, Suture; Complications, Infection or Inflammation, Rectal Diseases, Gastrointestinal Diseases
Keywords
PexyEazy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PexyEazy procedure
Arm Type
Experimental
Arm Description
PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
Intervention Type
Device
Intervention Name(s)
PexyEazy
Intervention Description
PexyEazy procedure on patients with hemorrhoidal disease grade II and III. The study is descriptive and non-comparable to evaluate the safety and performance of PexyEazy.
Primary Outcome Measure Information:
Title
Surgical result
Description
Clinical evaluation that a proper mucopexy has been achieved above all three locations (3, 7 and 11 o'clock) and any signs of bleeding or other damage to the mucosa, which is documented by the surgeon and by photography.
Time Frame
Directly after the surgical procedure
Title
Validation of device
Description
The handling and performance of the device is validated through a questionnaire that the surgeon fills out after the procedure.
Time Frame
Directly after the surgical procedure.
Title
Registered duration of surgery
Description
Duration of surgery (minutes)
Time Frame
Directly after the surgical procedure.
Title
Presence of pain
Description
The patient fill in a questionnaire with a scale between 1 and 10, where 1 is no pain and 10 is the worst possible pain.
Time Frame
Directly after the surgical procedure.
Title
Need of anesthesia, pain relief or local anesthesia
Description
The need for per-operative anesthesia and/or sedation and/or pain relied (morphine) and/or local anesthesia will be registered.
Time Frame
Directly after the surgical procedure.
Title
Per-operative complications
Description
Adverse events (both complication and device malfunction) during or directly after the procedure, which will be registered by a questionnaires filled in by patient and surgeon.
Time Frame
Directly after the surgical procedure.
Secondary Outcome Measure Information:
Title
Use of pain relief drugs after surgery
Description
The use of pain relief drugs (name of drug, dosage, number/day)
Time Frame
1 week, 3 months and 5 years after surgery
Title
Pain after surgery
Description
The patient fill in a questionnaire with a scale between 1 and 10, where 1 is no pain and 10 is the worst possible pain.
Time Frame
1 week, 3 months and 5 years after surgery
Title
Post operative complications
Description
Registration of any post-operative complications (fecal incontinence, anal stenosis, bleeding, perianal hematoma, urinary retention or incontinence, presence of infection/abscess and assessment by Clavien-Dindo classification).
Time Frame
1 week, 3 months and 5 years after surgery
Title
Clinical outcome
Description
Evaluation of the rectum and anal canal 3 months after the procedure to register presence of complications and recurrence of the hemorrhoidal disease. The result is documented by the surgeon and by a photography of the mucosa.
Time Frame
3 months after surgery
Title
Change of symptoms
Description
Change of hemorrhoid symptoms through a questionnaire called Hemorrhoidal Disease Symptom Score and Hemorrhoidal Disease Symptom Score (HDSS and HSS). The score can vary between 4-28.The higher the value, the more severe/worse symptoms.
Time Frame
Before the procedure, 1 week, 3 months and 5 years after the procedure.
Title
Change in quality of life
Description
Change in quality of life through a questionnaire called 36-Item Short Form Health Survey (SF-36). The score can vary between 0-100.The higher the value, the better quality of life.
Time Frame
Before the procedure, 3 months and 5 years after the procedure.
Title
Duration of sick-leave/unable to perform normal activities.
Description
The patient fills in a questionnaire about how long and to what degree the patient needed sick-leave or were not able to perform normal activities (in case the patient does not work).
Time Frame
1 week, 3 months and 5 years after surgery
Other Pre-specified Outcome Measures:
Title
Cost
Description
Calculate the total cost of the procedure including the cost for treatment of any complications, use of pain relief drugs and sick leave during the 3 month follow up period.
Time Frame
3 month and 5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
84 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult Hemorrhoidal disease grade II and III American Society of Anesthesiologists (ASA) classification I-III. Exclusion Criteria: Previous surgical treatment for hemorrhoids by all methods except rubber band ligation or sclerosing injection therapy within the last 3 years. Previous surgical treatment with rubber band ligation or injection therapy within the last 2 months. More than three surgical treatments with rubber band ligation or sclerosing injection therapy within the last 3 years. Under medication with immunosuppressive drugs and/or anticoagulant drugs (not including 75mg acetylsalicylic acid) and not able to interrupt the anticoagulant drug medication or replace it with low molecular weight heparin for 5 days. Have ulcerative colitis, Crohn's disease or other intestinal inflammatory disease or presence of inflamed or thickened mucosa of the rectum. Presence of anal fissure, anal stenosis, stricture, fistulas or ulcers in the rectal area. The rectum has not been prepared prior to the investigation with rectal enema and is contaminated with feces that cannot easily be removed. Have schizophrenia, untreated depression or other mental illness or conditions that may affect judgment, sensation of pain or inability to complete the follow-up. Under medication of morphine or other strong painkillers, not including paracetamol. Fecal incontinence (not including soiling due to hemorrhoidal disease), or conditions with impaired sensation in the rectal area or impaired function of the anal sphincter. Previous rectal radiation. Rectal cancer or previous surgery due to rectal cancer. Pregnancy Hypercoagulability disorders or diseases that result in increased risk of bleeding. Impaired immune system or condition that increases the risk of infection.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Johan Ungerstedt, Dr
Phone
+46709427842
Email
johan.ungerstedt@developeration.se
First Name & Middle Initial & Last Name or Official Title & Degree
Ulf Kressner, Dr
Email
ulfkressner@icloud.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ulf Kressner, Dr
Organizational Affiliation
Norrtälje Sjukhus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Frölunda Specialistsjukhus
City
Frölunda
ZIP/Postal Code
42144
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simone Schult, MD
Email
simone.schult@vgregion.se
Facility Name
Norrtälje Sjukhus
City
Norrtälje
ZIP/Postal Code
76129
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ulf Kressner, Dr
Email
ulfkressner@icloud.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
If data from the study is to be used for meta-analysis or review articles it will be shared upon request.
IPD Sharing Time Frame
From the start of the study to the end of the study.
IPD Sharing Access Criteria
E-mail to office@developeration.se for requesting information.
Citations:
PubMed Identifier
18766355
Citation
Aigner F, Gruber H, Conrad F, Eder J, Wedel T, Zelger B, Engelhardt V, Lametschwandtner A, Wienert V, Bohler U, Margreiter R, Fritsch H. Revised morphology and hemodynamics of the anorectal vascular plexus: impact on the course of hemorrhoidal disease. Int J Colorectal Dis. 2009 Jan;24(1):105-13. doi: 10.1007/s00384-008-0572-3. Epub 2008 Sep 3.
Results Reference
result
PubMed Identifier
26787597
Citation
Aigner F, Kronberger I, Oberwalder M, Loizides A, Ulmer H, Gruber L, Pratschke J, Peer S, Gruber H. Doppler-guided haemorrhoidal artery ligation with suture mucopexy compared with suture mucopexy alone for the treatment of Grade III haemorrhoids: a prospective randomized controlled trial. Colorectal Dis. 2016 Jul;18(7):710-6. doi: 10.1111/codi.13280.
Results Reference
result
PubMed Identifier
22033542
Citation
Gupta PJ, Kalaskar S, Taori S, Heda PS. Doppler-guided hemorrhoidal artery ligation does not offer any advantage over suture ligation of grade 3 symptomatic hemorrhoids. Tech Coloproctol. 2011 Dec;15(4):439-44. doi: 10.1007/s10151-011-0780-7. Epub 2011 Oct 28.
Results Reference
result

Learn more about this trial

SCI-Pex Study - Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids

We'll reach out to this number within 24 hrs